XJPX2397
Market cap26mUSD
Jan 09, Last price
650.00JPY
1D
1.88%
1Q
-9.34%
Jan 2017
14.84%
Name
DNA Chip Research Inc
Chart & Performance
P/E
—
P/S
8.42
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
4.94%
Revenues
490m
+49.74%
Net income
-248m
L-31.48%
CFO
-140m
L-58.35%
Profile
DNA Chip Research Inc. develops DNA microarrays in Japan. The company offers research and development, contract research, and diagnostic support services. It offers Tbone EX Kit for Japanese forensic laboratories in police force and universities. The company also develops EGFR (epidermal growth factor receptor) Liquid gene analysis software, a disease diagnosis program for detecting mutations in the gene encoding EGFR using DNA extracted from plasma samples or cancer tissues and determining drug efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer, as well as focuses on developing a gene panel for testing cancers using sequencing technology. The company was incorporated in 1999 and is based in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 490,462 49.74% | 327,535 -23.46% | 427,935 31.87% | ||
Cost of revenue | 748,540 | 690,114 | 593,719 | ||
Unusual Expense (Income) | |||||
NOPBT | (258,078) | (362,579) | (165,784) | ||
NOPBT Margin | |||||
Operating Taxes | 1,900 | 1,346 | 950 | ||
Tax Rate | |||||
NOPAT | (259,978) | (363,925) | (166,734) | ||
Net income | (248,293) -31.48% | (362,343) 170.31% | (134,046) -22.28% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 269,054 | 278,317 | |||
BB yield | -2.65% | -6.52% | |||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 41,270 | 38,989 | 10,180 | ||
Net debt | (447,406) | (343,361) | (524,154) | ||
| Cash flow | |||||
Cash from operating activities | (140,232) | (336,713) | (72,974) | ||
CAPEX | (15,860) | (126,128) | (58,672) | ||
Cash from investing activities | (15,775) | (155,397) | (58,672) | ||
Cash from financing activities | 269,054 | 278,317 | |||
FCF | (218,011) | (481,543) | (151,250) | ||
| Balance | |||||
Cash | 388,406 | 275,361 | 489,154 | ||
Long term investments | 59,000 | 68,000 | 35,000 | ||
Excess cash | 422,883 | 326,984 | 502,757 | ||
Stockholders' equity | (222,628) | (109,335) | 108,949 | ||
Invested Capital | 996,255 | 852,608 | 669,950 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 6,355 | 5,867 | 5,790 | ||
Price | 1,599.00 119.64% | 728.00 67.36% | 435.00 -38.21% | ||
Market cap | 10,162,110 137.93% | 4,271,022 69.59% | 2,518,460 -36.98% | ||
EV | 9,714,704 | 3,928,661 | 1,994,306 | ||
EBITDA | (216,222) | (344,760) | (149,313) | ||
EV/EBITDA | |||||
Interest | 1,506 | ||||
Interest/NOPBT | |||||